Wilson Sonsini Goodrich & Rosati advised Ginger on the deal, while Latham & Watkins represented Headspace. Ginger, a leading provider of on-demand mental healthcare, and Headspace, a...
Ginger’s Merger with Headspace
Aligos Therapeutics’ $83.6 Million Public Offering
Latham & Watkins LLP represented Aligos Therapeutics, while Davis Polk advised the representatives of the several underwriters in the offering. Aligos Therapeutics, Inc. (Nasdaq: ALGS) announced...
GlaxoSmithKline’s Collaboration with Alector
Latham & Watkins LLP represented GSK in the transaction. Alector, Inc. and GlaxoSmithKline plc, announced a strategic global collaboration for the development and commercialization of two...
GlaxoSmithKline’s Collaboration with Alector
Latham & Watkins LLP represented GSK in the transaction. Alector, Inc. and GlaxoSmithKline plc, announced a strategic global collaboration for the development and commercialization of two...
Valo Health’s $2.8 Billion Merger with Khosla Ventures Acquisition Co.
Goodwin Procter LLP advised Valo Health on the deal, while Latham & Watkins LLP represented Khosla Ventures Acquisition Co. Valo Health announced its definitive merger agreement with...
Frontier Group Holdings’ $570 Million Initial Public Offering
Latham & Watkins LLP represented Frontier, while Davis Polk advised the representatives of the several underwriters in the offering. Frontier Group Holdings, Inc. (Frontier), a low-cost...
Senda Biosciences’ Collaboration with Nestlé Health Science
Latham & Watkins LLP represented Senda Biosciences in the transaction. Senda Biosciences, a therapeutics platform company creating novel categories of medicines based on a new field...